BIONTECH/GENEVANT-SCI

10.7.2018 07:02:13 CEST | Business Wire | Press release

BioNTech and Genevant Sciences Sign Strategic mRNA-Focused Partnership in Rare Diseases

BioNTech AG and Genevant Sciences today announced that they have entered into a collaboration to develop five mRNA therapeutic programs for rare diseases with high unmet medical need. The companies have also agreed a series of exclusive licenses covering the application of Genevant’s delivery technology to five of BioNTech’s oncology programs. Genevant is eligible to receive significant commercial milestones for the oncology licenses.

The collaboration in rare diseases will combine Genevant’s industry-leading lipid nanoparticle (LNP) delivery technology with BioNTech’s cutting-edge mRNA drug discovery platform to develop best-in-class therapeutics. Both companies have established GMP-grade manufacturing capabilities and infrastructure.

Under the terms of the agreement, Genevant and BioNTech will pursue the co-development and co-commercialization of five mRNA programs. Genevant and BioNTech will share all future costs and profits for these programs on a 50/50 basis. The companies aim to initiate clinical development in 2020.

In addition to its strengths in cell and gene therapies and protein therapeutics, BioNTech is an industry leader in mRNA therapy development with extensive scientific expertise, manufacturing infrastructure, broad academic networks, and a deep understanding of mechanisms of action and clinical applications for this technology. It also has an innovative, scalable, ‘just-in-time’ manufacturing capability to produce its tailored treatments for patients.

“This partnership with Genevant will allow us to access a highly potent, clinically validated LNP delivery platform,” said Prof. Ugur Sahin, Co-Founder and Chief Executive Officer of BioNTech . “Genevant’s liver-targeted platform complements our existing capabilities for dendritic cell-specific delivery of mRNA encoded antigens used in the development of our cancer vaccine pipeline.”

Genevant’s LNP platform is the only clinically-validated LNP delivery technology, the safety and efficacy of which has been evaluated in over 400 patients across multiple clinical programs. Genevant’s delivery technologies can facilitate therapeutic approaches covering a broad spectrum of payloads. Genevant has begun development on numerous programs across multiple RNA modalities.

“This 50/50 partnership to develop rare disease mRNA therapeutics recognizes the critical importance of both best-in-class nucleic acids and their delivery in RNA drug development,” said Paris Panayiotopoulos, Executive Chairman of Genevant. “BioNTech’s impressive molecular design expertise and Genevant’s leadership in RNA delivery are the ideal combination for developing cutting edge mRNA therapies for rare disease patients who have limited or no treatment options today.”

About BioNTech

BioNTech is Europe’s largest privately-held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases. The Company combines all building blocks for individualized immunotherapy under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based medicines through innovative chimeric antigen receptors and T-cell receptor-based products to novel checkpoint immunomodulators and small molecules. BioNTech’s commercial approach is validated by five top-tier corporate partnerships with Genentech, Genmab, Eli Lilly, Sanofi and Bayer Animal Health and its scientific approach through over 60 peer-reviewed scientific publications, including five publications in Nature. Founded in 2008, BioNTech’s financial shareholders include the Struengmann Family Office as its majority shareholder, Fidelity Management & Research Company, Invus, Janus Henderson Investors, MIG Fonds, Redmile Group, Salvia and several European family offices.

For more information, see www.biontech.de .

About Genevant Sciences

Genevant Sciences aims to deliver innovative and clinically meaningful therapies that improve the lives of patients with genetic disorders by developing products in-house and forming partnerships to build a diverse pipeline of RNA therapeutics across multiple modalities. Through its proprietary delivery platforms, Genevant is able to pursue mRNA, RNAi, and gene editing modalities and select the optimal approach for any given disease.

Genevant expects to have 5 to 10 RNA programs in the clinic by 2020 targeting a range of genetic disorders with limited or no treatment options. For more information, please visit www.genevant.com .

About Business Wire

Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OpZira, Inc. Launches to Advance Ophthalmic Diagnostics with Innovative Medical Device Portfolio3.9.2025 19:23:00 CEST | Press release

OpZira™, Inc., a forward-thinking ophthalmic medical device company founded on a legacy of research excellence, today announced its official formation. OpZira is dedicated to delivering innovative technologies that enhance the detection and monitoring of ocular disease, empowering clinicians with advanced diagnostic tools. OpZira’s creation follows Alcon’s acquisition of LumiThera (https://www.alcon.com/media-release/alcon-completes-acquisition-lumithera/) and its innovative Valeda® Light Delivery System, the first and only FDA-authorized treatment for dry age-related macular degeneration (AMD). As part of the transaction, LumiThera’s diagnostic product lines were spun off to LumiThera shareholders, leading to the establishment of OpZira, Inc. OpZira’s product portfolio includes: AdaptDx Pro® – A wearable dark adaptometer that leverages AI to ensure a consistent patient experience. Impaired dark adaptation speed, a key early indicator of rod-mediated dysfunction, is often among the fir

BTG Bioliquids and NanosTech Partner to Deliver End-to-End Advanced Biofuels Solution3.9.2025 18:19:00 CEST | Press release

BTG Bioliquids BV (BTL), a Netherlands-based leader in fast pyrolysis technology, and NanosTech Technology & Innovations Ltd. (NanosTech), a Canada-based catalyst development and manufacturing company, have signed a Memorandum of Understanding (MOU) to deliver a fully integrated solution to produce advanced, drop-in biofuels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903698730/en/ The partnership combines BTL’s proven fast pyrolysis technology, which converts sustainable biomass into bio-oil, with NanosTech’s proprietary Aquaprocessing (AQP) platform, which upgrades even the most challenging bio-oils into refinery-ready feedstocks to produce fuels such as sustainable aviation fuel (SAF), renewable diesel, and marine fuels. The two companies are now actively collaborating to determine the location in Canada and Europe for the new 500-barrel-per-day modular biorefinery system. This system can be deployed near the feeds

Armis Named a Leader in IoT Security Solutions, Q3 2025 Evaluation3.9.2025 15:58:00 CEST | Press release

Recognition follows Armis being named a Leader in Unified Vulnerability Management Solutions evaluation Armis, the cyber exposure management & security company, today announced that it has been named a Leader in The Forrester Wave™: IoT Security Solutions, Q3 2025. This achievement comes on the heels of Armis being named a Leader in The Forrester Wave™: Unified Vulnerability Management Solutions, Q3 2025. In this Forrester Wave™, Armis is ranked a Leader and achieved the highest scores possible in 9 key criteria. According to the report, “Armis’ vision centers on delivering enterprise-wide exposure management that goes beyond IoT and OT devices. Its innovation investments and acquisitions support this goal. Its roadmap aligns with customer priorities while anticipating future needs to ensure the platform evolves alongside its clients. This forward-looking strategy fosters successful adoption and helps customers deploy the Centrix platform successfully.” “We’re proud to once again be re

Rapid Medical™ Surpasses 1,000 Cases With DRIVEWIRE™ 24 in North America and Expands Into Europe With MDR Approval3.9.2025 15:46:00 CEST | Press release

Clinical performance and strong physician demand drive swift uptake and global approval of next-generation access technology Rapid Medical™, a leading developer of active endovascular devices, announces that its DRIVEWIRE™ 24 steerable guidewire has been used in more than 1,000 neurovascular procedures in North America during a limited commercial launch beginning earlier this year. The company also announced receipt of CE Mark under the European Medical Device Regulation (MDR), as presented at the 2025 ESMINT Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903530140/en/ “In my experience, the wire provides a unique combination of precision and support that simply hasn’t been possible with conventional technologies,” stated Dr. Erez Nossek, a neurosurgeon at NYU Langone in New York, NY. “It has become a reliable tool that allows us to approach any anatomy with greater efficiency and less time.” As the first

Ondo Finance and Alpaca Collaborate to Tokenize US Stocks and ETFs3.9.2025 15:30:00 CEST | Press release

Bridging traditional finance and on-chain markets, increasing access to high-quality assets Today, Ondo Finance, a leader in blockchain-based financial innovation and tokenized real-world assets, announced the launch of Ondo Global Markets, their platform for tokenized US stocks and ETFs. The platform is powered by a strategic integration with Alpaca, a self-clearing broker-dealer and brokerage infrastructure API for stocks, ETFs, and options trading, as well as crypto. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903244835/en/ Ondo Finance and Alpaca collaborate to tokenize US stocks and ETFs; bridging traditional finance and on-chain markets, increasing access to high-quality assets. According to a McKinsey report, the tokenized market capitalization could reach around $2 trillion by 2030 across a variety of asset classes. This expected rise in market demand for tokenized assets, like US stocks and ETFs, comes as glob

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom